Aprea Therapeutics
Aprea Therapeutics is a biopharmaceutical company focused on developing novel DNA damage response (DDR) targeted cancer therapeutics. They aim to revolutionize cancer treatment by exploiting vulnerabilities in cancer cell mutations, with potential applications across multiple cancer types. Their mission is to develop groundbreaking, precision therapeutics for genetically defined cancers, with a focus on DDR pathways such as ATR and WEE1. The company is committed to advancing innovative therapies through clinical trials, aiming to benefit patients with limited treatment options.
Industries
Nr. of Employees
small (1-50)
Aprea Therapeutics
Patents
Aqueous solution comprising 3-quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease
US-9061016-B2
View Details
Aqueous solution comprising 3-quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease
US-9061016-B2
View DetailsProducts
APR-1051 (WEE1 inhibitor)
Orally administered selective small-molecule inhibitor of WEE1 kinase developed for advanced solid tumors; evaluated in a first-in-human Phase 1 dose-escalation study with biomarker-driven cohorts.
ATRN-119 (ATR inhibitor)
A macrocyclic small-molecule inhibitor targeting the ATR kinase developed for advanced solid tumors; evaluated in a first-in-human Phase 1/2a study with biomarker-driven enrollment and early signals of tumor response.
APR-1051 (WEE1 inhibitor)
Orally administered selective small-molecule inhibitor of WEE1 kinase developed for advanced solid tumors; evaluated in a first-in-human Phase 1 dose-escalation study with biomarker-driven cohorts.
ATRN-119 (ATR inhibitor)
A macrocyclic small-molecule inhibitor targeting the ATR kinase developed for advanced solid tumors; evaluated in a first-in-human Phase 1/2a study with biomarker-driven enrollment and early signals of tumor response.
Services
Sponsorship and operational execution of Phase 1/1-2a oncology clinical trials with biomarker-driven enrollment.
Development and integration of translational biomarker strategies to support precision enrollment and interpret pharmacodynamic responses in clinical studies.
Engagement with external institutions and precision medicine partners to access specialized facilities and expand development pathways.
Sponsorship and operational execution of Phase 1/1-2a oncology clinical trials with biomarker-driven enrollment.
Development and integration of translational biomarker strategies to support precision enrollment and interpret pharmacodynamic responses in clinical studies.
Engagement with external institutions and precision medicine partners to access specialized facilities and expand development pathways.
Expertise Areas
- DDR-targeted oncology therapeutics
- Small-molecule drug discovery and medicinal chemistry
- Preclinical pharmacology and in vivo efficacy studies
- Translational biomarker development
Key Technologies
- Oral small-molecule inhibitors
- Macrocyclic small-molecule design
- Synthetic lethality targeting of DDR pathways
- Kinase selectivity profiling